INSMED Inc. Announces Board and CFO Changes

Ticker: INSM · Form: 8-K · Filed: 2025-04-17T00:00:00.000Z

Sentiment: neutral

Topics: management-change, board-of-directors, cfo-appointment

TL;DR

INSMED shakes up leadership: new board members and a new CFO appointed.

AI Summary

On April 16, 2025, INSMED Incorporated announced changes in its executive leadership. The company elected two new directors, Dr. Ann M. D. Smith and Mr. David M. Stack, to its Board of Directors, effective immediately. Additionally, the company appointed Mr. Michael L. Smith as its new Chief Financial Officer, succeeding Mr. William M. Smith who will transition to a senior advisory role.

Why It Matters

These executive and board changes could signal a strategic shift or a response to recent performance, potentially impacting investor confidence and future company direction.

Risk Assessment

Risk Level: medium — Changes in key executive and board positions can introduce uncertainty regarding future strategy and operational stability.

Key Players & Entities

FAQ

Who were the new directors elected to INSMED's Board?

Dr. Ann M. D. Smith and Mr. David M. Stack were elected as new directors.

When were these board changes effective?

The election of the new directors was effective as of April 16, 2025.

Who has been appointed as the new Chief Financial Officer?

Mr. Michael L. Smith has been appointed as the new Chief Financial Officer.

What is the role of the outgoing CFO, Mr. William M. Smith?

Mr. William M. Smith will transition to a senior advisory role.

What is the primary business of INSMED Incorporated?

INSMED Incorporated is in the Pharmaceutical Preparations industry, SIC code 2834.

From the Filing

0001140361-25-014376.txt : 20250417 0001140361-25-014376.hdr.sgml : 20250417 20250417160204 ACCESSION NUMBER: 0001140361-25-014376 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250416 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20250417 DATE AS OF CHANGE: 20250417 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INSMED Inc CENTRAL INDEX KEY: 0001104506 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 541972729 STATE OF INCORPORATION: VA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-30739 FILM NUMBER: 25847201 BUSINESS ADDRESS: STREET 1: 700 US HIGHWAY 202/206 CITY: BRIDGEWATER STATE: NJ ZIP: 08807 BUSINESS PHONE: 908-977-9900 MAIL ADDRESS: STREET 1: 700 US HIGHWAY 202/206 CITY: BRIDGEWATER STATE: NJ ZIP: 08807 FORMER COMPANY: FORMER CONFORMED NAME: INSMED INC DATE OF NAME CHANGE: 20000128 8-K 1 ef20047566_8k.htm 8-K false 0001104506 0001104506 2025-04-16 2025-04-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2025 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 700 US Highway 202/206 Bridgewater , New Jersey   08807 (Zip Code) (Address of principal executive offices)     Registrant’s telephone number, including area code: ( 908 ) 977-9900 Not Applicable (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.01 per share INSM Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ ITEM 5.02 – Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers .   On April 16, 2025, J. Drayton Wise notified Insmed Incorporated (the “Company”) of his decision to resign from his position as the Company’s Chief Commercial Officer for personal and medical reasons, effective immediately. Mr. Wise’s resignation was not related to the Company’s financial or operating results or to any disagreements or concerns between Mr. Wise and the Company regarding the Company’s operations, policies, or practices.   Mr. Wise will continue to provide consulting services to the Company following his resignation as described in

View on Read The Filing